This is in accordance with studies showing that suppression of NKG2D-mediated antitumor functions can be correlated with high TGF-β1 plasma levels in neuroblastoma and colorectal cancer patients (42, 43). The gene discussed is TGFB1; the disease is neuroblastoma.